Arcus Biosciences, Inc. (RCUS) Guidance & Earnings Results
On 2026-02-25 Arcus Biosciences, Inc. reaffirmed guidance: "Cash runway until at least 2H…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RCUSArcus Biosciences, Inc.Follow RCUS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 25 Feb 26 | Reaffirmed | Cash runway until at least 2H 2028 · full year |
| 6 Aug 25 | Reaffirmed | FY25 GAAP revenue $225-235M; R&D expenses to decline from Q4 2025 · full year |
Arcus Biosciences, Inc. — questions
- What guidance did Arcus Biosciences, Inc. give?
- On 2026-02-25: "Cash runway until at least 2H 2028"
- When does Arcus Biosciences, Inc. report earnings?
- Arcus Biosciences, Inc.'s next earnings report is expected on 2026-11-10.
Every figure on this page comes from Arcus Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.